Silence Therapeutics Could Rival Amgen And Novartis With siRNA Therapy

Early Results Attract Big Pharma Interest

 
• By Andrew McConaghie
Cardiovascular
SLN360 is one of a wave of new RNA-based therapies targeting lipoprotein(a) (Lp(a) . • Source: Alamy

More from Clinical Trials

More from R&D